TY - JOUR
T1 - G-Protein biased opioid agonists
T2 - 3-hydroxy-: N -phenethyl-5-phenylmorphans with three-carbon chain substituents at C9
AU - Gutman, Eugene S.
AU - Bow, Eric
AU - Li, Fuying
AU - Sulima, Agnieszka
AU - Kaska, Sophia
AU - Crowley, Rachel
AU - Prisinzano, Thomas E.
AU - Lee, Yong Sok
AU - Hassan, Sergio A.
AU - Imler, Gregory H.
AU - Deschamps, Jeffrey R.
AU - Jacobson, Arthur E.
AU - Rice, Kenner C.
N1 - Publisher Copyright:
© 2020 The Royal Society of Chemistry.
PY - 2020/8
Y1 - 2020/8
N2 - A series of compounds have been synthesized with a variety of substituents based on a three-carbon chain at the C9-position of 3-hydroxy-N-phenethyl-5-phenylmorphan (3-(2-phenethyl-2-azabicyclo[3.3.1]nonan-5-yl)phenol). Three of these were found to be μ-opioid receptor agonists in the inhibition of forskolin-induced cAMP accumulation assay and they did not recruit β-arrestin at all in the PathHunter assay and in the Tango assay. Compound 12 (3-((1S,5R,9R)-2-phenethyl-9-propyl-2-azabicyclo[3.3.1]nonan-5-yl)phenol), 13 (3-((1S,5R,9R)-9-((E)-3-hydroxyprop-1-en-1-yl)-2-phenethyl-2-azabicyclo[3.3.1]nonan-5-yl)phenol), and 15a (3-((1S,5R,9R)-9-(2-hydroxypropyl)-2-phenethyl-2-azabicyclo[3.3.1]nonan-5-yl)phenol) were partial μ-agonists. Two of them had moderate efficacies (EMAXca. 65%) and one had lower efficacy, and they were ca. 5, 3, and 4 times more potent, respectively, than morphine in vitro. Computer simulations were carried out to provide a molecular basis for the high bias ratios of the C9-substituted 5-phenylmorphans toward G-protein activation.
AB - A series of compounds have been synthesized with a variety of substituents based on a three-carbon chain at the C9-position of 3-hydroxy-N-phenethyl-5-phenylmorphan (3-(2-phenethyl-2-azabicyclo[3.3.1]nonan-5-yl)phenol). Three of these were found to be μ-opioid receptor agonists in the inhibition of forskolin-induced cAMP accumulation assay and they did not recruit β-arrestin at all in the PathHunter assay and in the Tango assay. Compound 12 (3-((1S,5R,9R)-2-phenethyl-9-propyl-2-azabicyclo[3.3.1]nonan-5-yl)phenol), 13 (3-((1S,5R,9R)-9-((E)-3-hydroxyprop-1-en-1-yl)-2-phenethyl-2-azabicyclo[3.3.1]nonan-5-yl)phenol), and 15a (3-((1S,5R,9R)-9-(2-hydroxypropyl)-2-phenethyl-2-azabicyclo[3.3.1]nonan-5-yl)phenol) were partial μ-agonists. Two of them had moderate efficacies (EMAXca. 65%) and one had lower efficacy, and they were ca. 5, 3, and 4 times more potent, respectively, than morphine in vitro. Computer simulations were carried out to provide a molecular basis for the high bias ratios of the C9-substituted 5-phenylmorphans toward G-protein activation.
UR - http://www.scopus.com/inward/record.url?scp=85090422253&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090422253&partnerID=8YFLogxK
U2 - 10.1039/d0md00104j
DO - 10.1039/d0md00104j
M3 - Article
AN - SCOPUS:85090422253
SN - 2632-8682
VL - 11
SP - 896
EP - 904
JO - RSC Medicinal Chemistry
JF - RSC Medicinal Chemistry
IS - 8
ER -